This immunotoxin (TP) comprising TGFα and a modified Pseudomonas exotoxin A (PE38) derived from Pseudomonas aeruginosa was developed for the treatment of EGFR-expressing malignant tumors such as brain tumors [39,40,41]. Here, TGFA is linked to brain neoplasm.